584 related articles for article (PubMed ID: 24977454)
1. [A new perspective in the treatment of non-small-cell lung cancer (NSCLC). Role of afatinib: An oral and irreversible ErbB family blocker].
Wislez M; Malka D; Bennouna J; Mortier L; Bensadoun RJ; Sicard J; Dielenseger P; Rey JB; Moro-Sibilot D; Scotté F
Bull Cancer; 2014 Jun; 101(6):647-52. PubMed ID: 24977454
[TBL] [Abstract][Full Text] [Related]
2. Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
Heigener DF; Schumann C; Sebastian M; Sadjadian P; Stehle I; Märten A; Lüers A; Griesinger F; Scheffler M;
Oncologist; 2015 Oct; 20(10):1167-74. PubMed ID: 26354527
[TBL] [Abstract][Full Text] [Related]
3. Afatinib for the treatment of advanced non-small-cell lung cancer.
Genova C; Rijavec E; Barletta G; Burrafato G; Biello F; Dal Bello MG; Coco S; Truini A; Alama A; Boccardo F; Grossi F
Expert Opin Pharmacother; 2014 Apr; 15(6):889-903. PubMed ID: 24646054
[TBL] [Abstract][Full Text] [Related]
4. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
Marquez-Medina D; Popat S
Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834
[TBL] [Abstract][Full Text] [Related]
5. Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer.
Keating GM
Drugs; 2014 Feb; 74(2):207-21. PubMed ID: 24435321
[TBL] [Abstract][Full Text] [Related]
6. Afatinib and lung cancer.
Jain P; Khanal R; Sharma A; Yan F; Sharma N
Expert Rev Anticancer Ther; 2014 Dec; 14(12):1391-406. PubMed ID: 25417728
[TBL] [Abstract][Full Text] [Related]
7. Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs.
Brückl W; Tufman A; Huber RM
Expert Rev Anticancer Ther; 2017 Feb; 17(2):143-155. PubMed ID: 27898252
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
[TBL] [Abstract][Full Text] [Related]
10. Afatinib in the treatment of EGFR mutation-positive NSCLC--a network meta-analysis.
Popat S; Mok T; Yang JC; Wu YL; Lungershausen J; Stammberger U; Griebsch I; Fonseca T; Paz-Ares L
Lung Cancer; 2014 Aug; 85(2):230-8. PubMed ID: 24929780
[TBL] [Abstract][Full Text] [Related]
11. Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.
Landi L; Tiseo M; Chiari R; Ricciardi S; Rossi E; Galetta D; Novello S; Milella M; D'Incecco A; Minuti G; Tibaldi C; Salvini J; Facchinetti F; Haspinger ER; Cortinovis D; Santo A; Banna G; Catino A; GiajLevra M; Crinò L; de Marinis F; Cappuzzo F
Clin Lung Cancer; 2014 Nov; 15(6):411-417.e4. PubMed ID: 25242668
[TBL] [Abstract][Full Text] [Related]
12. [Afatinib in patients with squamous cell carcinoma of the lung: current context and the option of oral treatment].
Cobo M; Gutiérrez V; Rodelo L; López O; Ruiz M; Godoy A
Med Clin (Barc); 2016 Apr; 146 Suppl 1():25-9. PubMed ID: 27426245
[TBL] [Abstract][Full Text] [Related]
13. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
Hasegawa Y; Ando M; Maemondo M; Yamamoto S; Isa S; Saka H; Kubo A; Kawaguchi T; Takada M; Rosell R; Kurata T; Ou SH
Oncologist; 2015 Mar; 20(3):307-15. PubMed ID: 25657199
[TBL] [Abstract][Full Text] [Related]
14. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
Takeda M; Okamoto I; Nakagawa K
Lung Cancer; 2015 Apr; 88(1):74-9. PubMed ID: 25704957
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of first-line afatinib versus chemotherapy in EGFR mutation positive pulmonary adenocarcinoma].
Sárosi V; Balikó Z
Magy Onkol; 2014 Dec; 58(4):325-9. PubMed ID: 25517450
[TBL] [Abstract][Full Text] [Related]
16. LUX-Lung 3: redundancy, toxicity or a major step forward? Afatinib as front-line therapy for patients with metastatic EGFR-mutated lung cancer.
Köhler J; Schuler M
Future Oncol; 2014 Mar; 10(4):533-40. PubMed ID: 24754585
[TBL] [Abstract][Full Text] [Related]
17. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
[TBL] [Abstract][Full Text] [Related]
18. [Afatinib as first-line therapy in mutation-positive EGFR. Results by type of mutation].
Vidal ÓJ
Med Clin (Barc); 2016 Apr; 146 Suppl 1():12-8. PubMed ID: 27426243
[TBL] [Abstract][Full Text] [Related]
19. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
Kashiwabara K; Semba H; Fujii S; Tsumura S
Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
[TBL] [Abstract][Full Text] [Related]
20. Afatinib for the treatment of patients with EGFR-positive non-small cell lung cancer.
Bowles DW; Weickhardt A; Jimeno A
Drugs Today (Barc); 2013 Sep; 49(9):523-35. PubMed ID: 24086949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]